The company’s presentation will highlight two late-stage assets currently moving through the development pipeline. The lead candidate, veverimer, is undergoing Phase 3 testing for metabolic acidosis in adults with chronic kidney disease. Alongside this, management will discuss the status of RBT-1, a therapy designed for patients undergoing cardiac surgery.

RBT-1 recently finished the PROTECT Phase 3 trial. While initial results indicate the need for further evaluation among high-risk patient groups, the drug has already secured both Breakthrough and Fast Track designations from the FDA. Following the formal presentation, Renibus executives will participate in one-on-one sessions with conference attendees to discuss the company's broader clinical strategy.